Ionis Pharmaceuticals Inc.
Rating
Updated: Sep 9, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the...
Latest News
4 days ago · fool.com
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish OutlookIonis has six commercial therapies, mostly focused on rare diseases. Zanvastro treats Alexander disease, a brain disorder.
5 days ago · marketbeat.com
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio SetbacksIonis Pharmaceuticals NASDAQ: IONS CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies.
8 days ago · seekingalpha.com
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptIonis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
14 days ago · seekingalpha.com
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptIonis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
15 days ago · fool.com
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.Cathie Wood has bought and sold the stock a lot, so don't follow her blindly. The company posted a loss in its last quarter, but revenue is growing robustly.
16 days ago · defenseworld.net
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down After Analyst DowngradeIonis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) shares gapped down prior to trading on Tuesday after Morgan Stanley lowered their price target on the stock from $110.00 to $104.00. The stock had previously closed at $58.09, but opened at $52.15. Morgan Stanley currently has an overweight rating on the stock. Ionis Pharmaceuticals shares last
20 days ago · seekingalpha.com
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease TranscriptIonis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
20 days ago · marketbeat.com
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease TreatmentIonis Pharmaceuticals NASDAQ: IONS said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene.
20 days ago · zacks.com
IONS Secures FDA Nod for Rare Brain Disorder Drug ZanvastroIonis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
21 days ago · gurufocus.com
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO⢠(zilganersen)
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IONS